Theravance Biopharma, Inc. (NASDAQ:TBPH) Short Interest Down 14.5% in April

Theravance Biopharma, Inc. (NASDAQ:TBPH) was the recipient of a significant decrease in short interest in April. As of April 15th, there was short interest totalling 6,430,000 shares, a decrease of 14.5% from the March 31st total of 7,520,000 shares. Based on an average trading volume of 367,200 shares, the days-to-cover ratio is presently 17.5 days. Approximately 14.7% of the company’s stock are short sold.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. BTIG Research began coverage on shares of Theravance Biopharma in a research note on Friday, April 12th. They set a “buy” rating and a $21.00 price objective for the company. Evercore ISI cut Theravance Biopharma from an “outperform” rating to an “inline” rating in a research report on Monday, January 8th.

Institutional Trading of Theravance Biopharma

Hedge funds have recently added to or reduced their stakes in the company. Newtyn Management LLC increased its stake in shares of Theravance Biopharma by 12.3% in the 3rd quarter. Newtyn Management LLC now owns 1,841,560 shares of the biopharmaceutical company’s stock valued at $15,893,000 after purchasing an additional 201,104 shares in the last quarter. Oasis Management Co Ltd. grew its holdings in Theravance Biopharma by 5.6% in the fourth quarter. Oasis Management Co Ltd. now owns 1,006,858 shares of the biopharmaceutical company’s stock valued at $11,317,000 after purchasing an additional 53,604 shares during the period. GSA Capital Partners LLP increased its position in shares of Theravance Biopharma by 1,536.4% in the third quarter. GSA Capital Partners LLP now owns 325,985 shares of the biopharmaceutical company’s stock valued at $2,813,000 after buying an additional 306,064 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Theravance Biopharma by 68.0% during the 4th quarter. Wellington Management Group LLP now owns 287,102 shares of the biopharmaceutical company’s stock worth $3,227,000 after buying an additional 116,164 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Theravance Biopharma by 4.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 44,532 shares of the biopharmaceutical company’s stock valued at $384,000 after buying an additional 1,993 shares in the last quarter. 99.10% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma Stock Performance

NASDAQ:TBPH opened at $8.44 on Wednesday. The firm’s fifty day moving average is $9.07 and its two-hundred day moving average is $9.67. The firm has a market cap of $409.85 million, a price-to-earnings ratio of -8.70 and a beta of 0.36. Theravance Biopharma has a one year low of $8.21 and a one year high of $11.98.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Theravance Biopharma had a negative return on equity of 19.31% and a negative net margin of 96.12%. The company had revenue of $17.57 million for the quarter, compared to analyst estimates of $17.49 million. As a group, equities research analysts predict that Theravance Biopharma will post -0.84 earnings per share for the current fiscal year.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.